These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 17107276)
21. [Off-label use in dermatological practice. The conflict between professional duty and legal requirements]. Brunne V; Mertins G; Reimann G; Brockmeyer NH Hautarzt; 2004 Aug; 55(8):727-34. PubMed ID: 15241515 [TBL] [Abstract][Full Text] [Related]
22. Thyroid-adrenocortical relationships in the safe treatment of arthritis, allergy, and skin disorders with prednisone. Barnes BO J Am Geriatr Soc; 1975 Dec; 23(12):548-50. PubMed ID: 1206190 [No Abstract] [Full Text] [Related]
23. The FDA Breakthrough-Drug Designation - Four Years of Experience. Darrow JJ; Avorn J; Kesselheim AS N Engl J Med; 2018 Apr; 378(15):1444-1453. PubMed ID: 29641970 [No Abstract] [Full Text] [Related]
25. [Development of new drugs is too expensive]. Andreasen J Ugeskr Laeger; 2003 May; 165(19):1959-60. PubMed ID: 12795066 [No Abstract] [Full Text] [Related]
26. A critical tipping point. Zuckerman MB US News World Rep; 2002 Apr; 132(13):72. PubMed ID: 11993366 [No Abstract] [Full Text] [Related]
27. Market watch: Upcoming market catalysts in Q3 2016. Ranj T Nat Rev Drug Discov; 2016 Jul; 15(7):449. PubMed ID: 27282354 [No Abstract] [Full Text] [Related]
28. [Therapeutic update]. Luyckx A; Scheen A; Van Cauwenberge H Rev Med Liege; 1986 May; 41(10):459-67. PubMed ID: 3526504 [No Abstract] [Full Text] [Related]
29. New drug development in the United States from 1963 to 1999. Dimasi JA Clin Pharmacol Ther; 2001 May; 69(5):286-96. PubMed ID: 11371996 [No Abstract] [Full Text] [Related]
31. Discontinued drugs in 2007: oncology drugs. Williams R Expert Opin Investig Drugs; 2008 Dec; 17(12):1791-816. PubMed ID: 19012497 [TBL] [Abstract][Full Text] [Related]
32. Support for trials of promising medications through the Pharmaceutical Benefits Scheme. Bell KD Med J Aust; 1995 Apr; 162(8):447; author reply 447-8. PubMed ID: 7746194 [No Abstract] [Full Text] [Related]
33. Clinical approval success rates for investigational cancer drugs. DiMasi JA; Reichert JM; Feldman L; Malins A Clin Pharmacol Ther; 2013 Sep; 94(3):329-35. PubMed ID: 23739536 [TBL] [Abstract][Full Text] [Related]
34. Discontinued drug projects in the respiratory therapeutic area during 2012. Snell NJ Expert Opin Investig Drugs; 2014 Mar; 23(3):411-5. PubMed ID: 24490845 [TBL] [Abstract][Full Text] [Related]
36. New estimates of drug development costs. Frank RG J Health Econ; 2003 Mar; 22(2):325-30. PubMed ID: 12606149 [No Abstract] [Full Text] [Related]
37. Digestive Disease Week 2005. Drug highlights II. De La Rue SA IDrugs; 2005 Jul; 8(7):539-41. PubMed ID: 15973558 [No Abstract] [Full Text] [Related]
38. Racial representation in clinical trials for dermatological new molecular entities. Ha MV; Wong C Clin Exp Dermatol; 2022 Feb; 47(2):386-388. PubMed ID: 34346107 [TBL] [Abstract][Full Text] [Related]
39. Ethical and financial considerations in third-party support of investigational cancer therapies. Young FE Cancer; 1993 Nov; 72(9 Suppl):2854-8. PubMed ID: 8402519 [TBL] [Abstract][Full Text] [Related]
40. Topical Drug Innovation From 2000 Through 2014. Walter JR; Xu S JAMA Dermatol; 2015 Jul; 151(7):792-4. PubMed ID: 25807060 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]